Annual Financial Report

Overview

The report describes Inventiva's 2019 clinical progress, including completion of patient enrollment in the NASH Phase IIb trial and continued development of its odiparcil program. It reports €6,998 thousand of revenue, alongside detailed environmental data including 6,902 cu. m of water consumption and energy-related CO2 emissions. The governance section reports three women among seven directors, representing 42.8% of the Board.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: Ends 31 December 2019
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Provider
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services